Pathogenic Mechanisms in C Diff Infection and Colitis

N/ACompletedNCT01930032

Beth Israel Deaconess Medical Center24 enrolled

Overview

The purpose of this study is to learn more about infection by Clostridium difficile (also known as C. difficile). C. difficile is a common bacterium (a germ that may cause disease) that can live in the human gut. Some people have it without having any symptoms. In other people it can cause illness ranging from mild diarrhea to severe colitis (infection of the colon). C. difficile makes toxins that damage the cells that line the colon. The study doctors want to find out how these toxins cause damage to the cells in the colon.

The purpose of this study is to examine pathogenic mechanisms of Clostridium difficile toxin-mediated intestinal injury and inflammation. Two primary mechanisms will be examined. * To examine the hypothesis is that microRNA expression profiles are dysregulated by Clostridium difficile toxin exposure and that dysregulation of miRNA expression plays a role in the pathogenesis of C. difficile associated diseases. * To examine the hypothesis is that the TLR9 receptor mediates key inflammatory events in response to Clostridium difficile toxin exposure.

Study Type

OBSERVATIONAL

Enrollment

Conditions

Clostridium Difficile Infection

Eligibility

Sex: ALLMin age: 18 YearsMax age: 75 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age greater than 18 yrs and less than 75 years * Undergoing a clinically indicated colonoscopy Exclusion Criteria: * Known, active or recurrent colonic disease including: Clostridium difficile infection, inflammatory bowel disease, microscopic colitis, colon resection for any reason, ischemic colitis, recurrent diverticulitis, colon cancer. Note: Diverticulosis without recurrent diverticulitis, colonic adenomatous or hyperplastic polyps or colonic arteriovenous malformations will not constitute an exclusion * Diarrhea (an average of more than 3 bowel movements per day at baseline) * Constipation (an average of fewer than 2 bowel movements per week at baseline). * Use of systemic steroid or systemic immunosuppressive medication * Severe renal impairment * Relative contraindication to colon biopsy including a bleeding diathesis or anti-coagulant use. Note: nonsteroidal antiinflammatory drug or asprin use will not constitute a contra-indication.

Locations (1)

Beth Israel Deaconess Medical Center

Boston, Massachusetts, United States

Outcomes

Primary Outcomes

Binding of Toxin A (and B) to TLR9 on the human colorectal epithelial cell surface

As assessed by confocal fluorescence microscopy

Time frame: 24 hours

Secondary Outcomes

effects of a TLR9 antagonist (ODN-TTAGGG) on toxin binding

The change of mean toxin fluorescence on colonocytes will be measured by confocal microscopy using quantitative image analysis software.

Time frame: 0 hours

Binding of Toxin A (and B) to TLR9 on the human colorectal epithelial cell surface

as assessed by confocal fluorescence microscopy

Time frame: 0 hours

Binding of Toxin A (and B) to TLR9 on the human colorectal epithelial cell surface

As assessed by confocal fluorescence microscopy

Time frame: 6 hours

Effects of a TLR9 antagonist (ODN-TTAGGG) on toxin binding

The change of mean toxin fluorescence on colonocytes will be measured by confocal microscopy using quantitative image analysis software.

Time frame: 6 hours

Effects of a TLR9 antagonist (ODN-TTAGGG) on toxin binding

The change of mean toxin fluorescence on colonocytes will be measured by confocal microscopy using quantitative image analysis software.

Time frame: 24 hours

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.